Ridaforolimus
- Generic Name
- Ridaforolimus
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C53H84NO14P
- CAS Number
- 572924-54-0
- Unique Ingredient Identifier
- 48Z35KB15K
- Indication
Investigated for use/treatment in solid tumors, sarcoma, cancer/tumors (unspecified), endometrial cancer, prostate cancer, and bone metastases.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT00694083
Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)
- Conditions
- Interventions
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 711
- Registration Number
- NCT00538239
Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 37
- Registration Number
- NCT00288431
AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00122343
Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 147
- Registration Number
- NCT00112372
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
- First Posted Date
- 2005-05-05
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 39
- Registration Number
- NCT00110188
- Locations
- 🇺🇸
Louis Warchaw Prostate Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Wisconsin, Madison, WI, Madison, Wisconsin, United States
🇺🇸Beth Israel Deaconess Medical Center/MGH/DFCI, Boston, Massachusetts, United States
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2004-10-04
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 216
- Registration Number
- NCT00093080
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2004-06-28
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00086125
- Locations
- 🇺🇸
University of Chicago Hospitals, Section of Hematology/Oncology, Chicago, Illinois, United States
🇺🇸The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)
- First Posted Date
- 2003-05-12
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 46
- Registration Number
- NCT00060632
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
- First Posted Date
- 2003-05-12
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 33
- Registration Number
- NCT00060645
- Locations
- 🇺🇸
Cancer Therapy and Research Center, University of Texas Health Center at San Antonio, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.